Rare Chance Or Passing Opportunity: China Expands Orphan Drug Coverage With Steep Price Cuts
Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.
You may also be interested in...
November negotiations in China over the prices of 67 new drugs have resulted in record price cuts, averaging around 62% overall and 65% for anti-tumor products. But the sting is alleviated by the prospect of substantial volume increases.
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.
An oral vaccine candidate from Hong Kong and domestically-developed antivirals and antibodies join the ongoing development fight as Tianjin city reports new Omicron outbreak.